FDA Approves AstraZeneca’s Fasenra as Add-On Maintenance Therapy for Children Aged 6 to 11 with Severe Asthma
Treatment was initially approved in 2017 for the same indication in children aged 12 and up.
Treatment was initially approved in 2017 for the same indication in children aged 12 and up.